Loading clinical trials...
Loading clinical trials...
Safety, PK/PD, and Efficacy of NOX-H94 in Dialysis Patients With ESA-hyporesponsive Anemia: A Randomized, Double Blind, Placebo Controlled Parallel Group Study With a Single Blind Cross-over Group
Conditions
Interventions
Lexaptepid pegol (NOX-H94)
Placebo
Locations
10
Germany
Dialysis Unit
Düsseldorf, Germany
University Hospital
Halle, Germany
Hospital
Leipzig, Germany
Dialysis Unit
Villingen-Schwenningen, Germany
Hospital
Siena, Italy
Hospital
Swansea, Wales, United Kingdom
Start Date
May 1, 2014
Primary Completion Date
November 1, 2015
Completion Date
November 1, 2015
Last Updated
November 24, 2015
NCT05012111
NCT03520647
NCT05447442
NCT06287268
NCT04645199
NCT03050268
Lead Sponsor
TME Pharma AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions